In patients with locally advanced breast cancer, neoadjuvant chemotherapy (NAC) followed by surgery has been the standard treatment, especially in those with human epidermal growth factor receptor 2 (HER2)-enriched or triple negative cancer types with a tumor size > 2 cm and/or axillary lymph node metastasis [2]. The gene discussed is ERBB2; the disease is breast carcinoma.